1-ethyl-4-(3-methoxyphenyl)piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-ethyl-4-(3-methoxyphenyl)piperazine
• 化学式: C₁₃H₂₀N₂O
• 分子量: 220.315
• InChiKey: FBVWQXPEPQGWJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  15.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-ethyl-4-(3-methoxyphenyl)piperazine 、 碘乙烷 在 铜 作用下， 以 四氢呋喃 为溶剂， 以76%的产率得到1,1-diethyl-4-(3-methoxyphenyl)piperazin-1-ium iodide
  参考文献：
  名称：

  Dissection of N,N-diethyl-N′-phenylpiperazines as α7 nicotinic receptor silent agonists

  摘要：

  The alpha 7 nicotinic acetylcholine receptor (nAChR) is a target for control of inflammation-related phenomena via compounds that are able to selectively induce desensitized states of the receptor. Compounds that selectively desensitize, without facilitating significant channel activation, are termed 'silent agonists' because they can be discriminated from antagonists by the currents evoked with co-application with type II positive allosteric modulators (PAMs). One example is N, N-diethyl-N'-phenyl-piperazine(diEPP) (J. Pharm. Exp. Ther. 2014, 350, 665). We used Ullmann-type aryl amination to synthesize a panel of 27 compounds related to diEPP by substitutions at the aryl ring and in the linkage between the piperazine and phenyl rings. Two-electrode voltage clamping of the human a7 nAChR expressed in Xenopus oocytes revealed that it was possible to tune the behavior of compounds to show enhanced desensitization without corresponding partial agonist activity such that trifluoromethyl and carboxamide aryl substituents showed 33 to 46-fold larger PAM-dependent net-charge responses, indicating selective partitioning of the ligand receptor complexes into the desensitized state. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.017
• 作为产物：
  描述：

  N-乙基哌嗪 、 3-碘苯甲醚 在 copper(l) iodide 、 potassium carbonate 、 L-脯氨酸 作用下， 以 二甲基亚砜 为溶剂， 以70%的产率得到1-ethyl-4-(3-methoxyphenyl)piperazine
  参考文献：
  名称：

  Dissection of N,N-diethyl-N′-phenylpiperazines as α7 nicotinic receptor silent agonists

  摘要：

  The alpha 7 nicotinic acetylcholine receptor (nAChR) is a target for control of inflammation-related phenomena via compounds that are able to selectively induce desensitized states of the receptor. Compounds that selectively desensitize, without facilitating significant channel activation, are termed 'silent agonists' because they can be discriminated from antagonists by the currents evoked with co-application with type II positive allosteric modulators (PAMs). One example is N, N-diethyl-N'-phenyl-piperazine(diEPP) (J. Pharm. Exp. Ther. 2014, 350, 665). We used Ullmann-type aryl amination to synthesize a panel of 27 compounds related to diEPP by substitutions at the aryl ring and in the linkage between the piperazine and phenyl rings. Two-electrode voltage clamping of the human a7 nAChR expressed in Xenopus oocytes revealed that it was possible to tune the behavior of compounds to show enhanced desensitization without corresponding partial agonist activity such that trifluoromethyl and carboxamide aryl substituents showed 33 to 46-fold larger PAM-dependent net-charge responses, indicating selective partitioning of the ligand receptor complexes into the desensitized state. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2015.12.017

文献信息

• [EN] NICOTINIC ACETYLCHOLINE RECEPTOR SILENT AGONISTS<br/>[FR] AGONISTES SILENCIEUX DU RÉCEPTEUR NICOTINIQUE D'ACÉTYLCHOLINE
  申请人：THE UNIV OF FLORIDA RES FOUND INC

  公开号：WO2017066558A1

  公开（公告）日：2017-04-20

  Derivatives of N,N-diethyl-N'- phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.

  N,N-二乙基-N'-苯基哌嗪的衍生物，作为哺乳动物α7尼古丁乙酰胆碱受体的沉默激动剂，已提供。这些沉默激动剂控制受体的耗散状态。还提供了允许将上述沉默激动剂给予需要治疗由炎症等病理状况引起的动物或人类的药物组合物。这种新型沉默激动剂也可以与II型正向变构调节剂同时或连续给予患者，以调节受体的活性。
• DIPEPTIDE NITRILES
  申请人：Altmann Eva

  公开号：US20080027060A1

  公开（公告）日：2008-01-31

  N-terminal substituted dipeptide nitriles as defined are useful as inhibitors of cysteine cathepsins, e.g. cathepsins B, K, L and S, and can be used for the treatment of cysteine cathepsin dependent diseases and conditions, including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis, tumors (especially tumor invasion and tumor metastasis), coronary disease, atherosclerosis (including atherosclerotic plaque rupture and destabilization). Particular dipeptide nitriles are compounds of formula I, or physiologically-acceptable and -cleavable esters or a salts thereof wherein: the symbols are as defined. In particular it has been found that by appropriate choice of groups R, R 2 , R 3 , R 4 , R 5 , X 1 , Y and L, the relative selectivity of the compounds as inhibitors of the various cysteine cathepsin types, e.g. cathepsins B, K, L and S may be altered, e.g. to obtain inhibitors which selectively inhibit a particular cathepsin type or combination of cathepsin types.

  N-末端取代二肽基腈可作为半胱氨酸蛋白酶的抑制剂，例如半胱氨酸蛋白酶B、K、L和S，并可用于治疗半胱氨酸蛋白酶依赖性疾病和病况，包括炎症、类风湿关节炎、骨关节炎、骨质疏松症、肿瘤（尤其是肿瘤侵袭和转移）、冠心病、动脉硬化（包括动脉粥样硬化斑块破裂和不稳定性）。特定的二肽基腈化合物为I式化合物，或其生理上可接受和可水解酯或其盐。其中：符号如定义。特别地，通过适当选择R、R2、R3、R4、R5、X1、Y和L基团，可以改变化合物作为各种半胱氨酸蛋白酶类型的抑制剂的相对选择性，例如获得选择性抑制特定半胱氨酸蛋白酶类型或半胱氨酸蛋白酶类型组合的抑制剂。
• 3-SUBSTITUTED-6-ARYL PYRIDINES
  申请人：Hutchinson Alan J.

  公开号：US20110281837A1

  公开（公告）日：2011-11-17

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I的3-取代-6-芳基吡啶化合物：其中R1、R2、R3、R8、R9、A和Ar的定义在此处。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合到C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的制药组合物，以及将这些化合物用于治疗各种炎症、心血管和免疫系统疾病的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体定位的探针。
• O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF
  申请人：Kahne Suzanne Walker

  公开号：US20120108605A1

  公开（公告）日：2012-05-03

  The present invention provides inhibitors of O-GIcNAc transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, neurodegenerative diseases, cancers, autoimmune diseases, and inflammatory diseases.

  本发明提供了O-GIcNAc转移酶的抑制剂。通常，这些抑制剂是喹啉酮-6-磺酰胺。本发明还提供了其制药组合物以及在糖尿病及其并发症、神经退行性疾病、癌症、自身免疫疾病和炎症性疾病中使用它们的方法。
• 3-Substituted-6-Aryl Pyridines
  申请人：Hutchison Alan J.

  公开号：US20090176980A1

  公开（公告）日：2009-07-09

  3-substituted-6-aryl pyridines of Formula I are provided: wherein R 1 , R 2 , R 3 , R 8 , R 9 , A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 3-substituted-6-aryl pyridines, which are useful as probes for the localization of C5a receptors.

  本发明提供了式I中的3-取代-6-芳基吡啶化合物： 其中R1、R2、R3、R8、R9、A和Ar在此定义。这些化合物是C5a受体的配体。式I的优选化合物具有高亲和力结合C5a受体，并在C5a受体上表现出中性拮抗剂或反向激动剂活性。本发明还涉及包含这些化合物的药物组合物，以及在治疗各种炎症，心血管和免疫系统疾病中使用这些化合物的用途。此外，本发明提供了标记的3-取代-6-芳基吡啶，可用作C5a受体的定位探针。